ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

2025Äê4ÔÂ25ÈÕ-4ÔÂ30ÈÕ£¬£¬£¬£¬£¬£¬£¬µÚ116½ìÃÀ¹ú°©Ö¢Ñо¿Ð­»á£¨AACR£©Äê»á½«ÓÚÔÚÃÀ¹úÖ¥¼Ó¸çÕÙ¿ª£¬£¬£¬£¬£¬£¬£¬AACRÄê»áÊÇÐû²¼°©Ö¢ÕïÁÆÑо¿Ï£ÍûÐÅÏ¢µÄÖ÷Òª¹ú¼ÊѧÊõ¾Û»á¡£¡£¡£¡£¡£¡£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾5Ïî×ÔÖ÷Ñз¢µÄ×îÐÂÑо¿Ð§¹ûÈëÑ¡2025ÄêAACRÄê»á²¢»ñÑû¾Û»áÏÖ³¡Õ¹Ê¾¡£¡£¡£¡£¡£¡£ÆäÖаüÀ¨ÓëÉϺ£´óѧÁ¥ÊôÃϳ¬Ö×ÁöҽԺ͎ῪչµÄ2ÏîÁ¢ÒìCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁƲúÆ·Ñо¿£º×ÔÉø͸PD1ÄÉÃ׿¹Ìå×°¼×»¯Ë«°ÐµãCAR-TÏîÄ¿£¨BZE2203£©ºÍ·Ç²¡¶¾Èý°ÐµãÎÞ×÷ÓýÉÁCAR-TÏîÄ¿£¨BZE2204£©£»£»£»£»£»ÒÔ¼°ÓëÆä×Ó¹«Ë¾ÃÀ¹úChantibody¹«Ë¾£¨CHANTIBODY THERAPEUTICS INC.£©ÏàÖú¾ÙÐеÄ3Ïî»ùÓÚÄÉÃ׿¹ÌåÊÖÒÕµÄÁ¢ÒìÒ©ÎïÑо¿ÏîÄ¿£ºPD-1*CTLA-4*VEGFÈý°ÐµãÌØÒìÐÔÄÉÃ׿¹Ì壨CT111£©¡¢CD3¼°Ö×ÁöÌØÒìÐ԰еãµÄTCE¿¹Ì壨CT224£©ºÍ»ùÓÚÈ˹¤ÖÇÄܵÄVHH¸ßͨÁ¿É¸Ñ¡Æ½Ì¨ÏîÄ¿£¨CARP£©¡£¡£¡£¡£¡£¡£

ÒÔCAR-T¡¢ÃâÒ߶࿹ºÍTCEΪ´ú±íµÄÖ×ÁöÃâÒßÖÎÁÆÊÖ¶ÎÕýÔÚ¿ìËÙË¢ÐÂÖ×ÁöÖÎÁÆÃûÌᣡ£¡£¡£¡£¡£ÆäÖУ¬£¬£¬£¬£¬£¬£¬CAR-TÁÆ·¨ÒÀ¸½Æä"Ò»ÕëÖÎÓú"µÄ»îÒ©ÎïÌØÕ÷£¬£¬£¬£¬£¬£¬£¬ÖÎÁƹæÄ£ÒÑ´ÓѪҺÖ×ÁöÀÖ³ÉÍØÕ¹ÖÁʵÌåÁöºÍ×ÔÉíÃâÒßÐÔ¼²²¡ÁìÓò£¬£¬£¬£¬£¬£¬£¬Îª¶àÖÖÄÑÖÎÐÔ¼²²¡´øÀ´È«Ð½â¾ö¼Æ»®¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬¸öÐÔ»¯ÖÎÁÆģʽµ¼Öµĸ߰º±¾Ç®ºÍÂþ³¤ÖƱ¸ÖÜÆÚ£¬£¬£¬£¬£¬£¬£¬ÈÔÊÇÏÞÖÆÆäÁÙ´²¿É¼°ÐÔºÍÉÌÒµ»¯Éú³¤µÄÖ÷Ҫƿ¾±¡£¡£¡£¡£¡£¡£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾±ü³Ö“ÁÆЧΪºË£¬£¬£¬£¬£¬£¬£¬ÀèÃñ¿É¼°”µÄÒ©Î￪·¢ÀíÄ£¬£¬£¬£¬£¬£¬Ò»Á¬Íƶ¯JL-ÉÁCAR-T™Îª½¹µãµÄÒªº¦ÊÖÒÕƽ̨¿ª·¢£¬£¬£¬£¬£¬£¬£¬ÊµÏÖÔ­Á¢ÒìÒ»´ú·Ç²¡¶¾ÔØÌå»ùÒòдÈëÊÖÒÕ¼°µÚËÄ´úÄÉÃ׿¹ÌåVHHMAb^®ÊÖÒյȵײãÊÖÒÕµÄÒ»Á¬Í»ÆÆ£¬£¬£¬£¬£¬£¬£¬¼ÓËÙÁ¢ÒìÖÎÁÆÒ©Î￪·¢Àú³Ì¡£¡£¡£¡£¡£¡£±¾´ÎÄê»á£¬£¬£¬£¬£¬£¬£¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÁ¢ÒìÑо¿Ð§¹ûϵͳµØչʾÁËÆäÔÚÖ×ÁöÃâÒßÖÎÁÆÁìÓòÁýÕִӵײãÊÖÒÕÍ»ÆƵ½ÓÅÊÆ¿¹Ìå·¢Ã÷£¬£¬£¬£¬£¬£¬£¬ÔÙ¹âÁÙ´²Ó¦ÓÃת»¯µÄÍêÕûÒ©Î￪·¢ÏµÍ³£¬£¬£¬£¬£¬£¬£¬ÎªÍƽøµÍ±¾Ç®¸ßÁÆЧµÄÖ×ÁöÖÎÁÆÁ¢ÒìÒ©Î￪·¢ÌṩÁ˼áʵ°ü¹Ü¡£¡£¡£¡£¡£¡£

ÒÔÏÂΪժҪÐÅÏ¢£º

BZE2203£º×ÔÉø͸¿¹PD-1ÄÉÃ׿¹Ìå×°¼×»¯Ë«°ÐÏòMUC1ºÍMSLNµÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁƲúÆ·

ÕªÒªÎÊÌ⣺MSLN and MUC1 dual-targeting CAR-T with conditional activation and tumor specificity to improve clinical safety and efficacy

·Ö»á³¡Ö÷Ì⣺CAR-T Cells

±àºÅ£º4799

ʱ¼ä£ºÃÀ¹ú¶«²¿Ê±¼ä4ÔÂ29ÈÕ£¨Öܶþ£©9:00 AM-12:00 PM

ËùÔÚ£ºµÚ37Çø£¬£¬£¬£¬£¬£¬£¬Õ¹°å#2

BZE2203½ÓÄÉÌõ¼þ¼¤»îÐÍCAR½á¹¹Éè¼Æ£¬£¬£¬£¬£¬£¬£¬ÒÀÍÐÓÚ¼¯ÍŵÚËÄ´úÄÉÃ׿¹ÌåVHHMAb^®ÊÖÒÕƽ̨¿ª·¢µÄÖ×ÁöÌØÒìÐÔÍŽáMUC1ÄÉÃ׿¹Ìå¡¢pHÒÀÀµµÄMSLNÄÉÃ׿¹ÌåºÍ¸ßÇ׺ÍÁ¦µÄPD-1ÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬£¬ÍŽá×ÔÖ÷Á¢ÒìµÄ»ùÒòдÈëϵͳºÍJL-ÉÁCAR-T™ÊÖÒÕƽ̨¿ª·¢µÄÃâÒß¼ì²éµã¿¹Ìå×°¼×»¯Ë«°ÐÏòµÄʵÌåÁöÉÁCAR-T¡£¡£¡£¡£¡£¡£¾ß±¸µÍ·Ö½âÌØ¡¢ÌåÄÚÔöÖ³¡¢Ò»Á¬ÐԺá¢×ÔÉø͸¿¹PD-1ÄÉÃ׿¹ÌåµÈÌØÕ÷£¬£¬£¬£¬£¬£¬£¬ÒÔ¼õÇáTME¶ÔCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºÍÖ×Áö½þÈóÁÜ°ÍÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÒÖÖÆ×÷Óᣡ£¡£¡£¡£¡£ÏÖÔÚ¿ªÕ¹µÄIITÁÙ´²ÊµÑéÖУ¬£¬£¬£¬£¬£¬£¬Ê×´ÎÈë×éµÄÁ½Àý²¬ÀàÄÍÒ©Âѳ²°©»¼Õߣ¬£¬£¬£¬£¬£¬£¬½ÓÊÜÁË5×10⁵CAR-T/kgµÍ¼ÁÁ¿CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾»ØÊä, ÁÙ´²ÊÓ²ìÇå¾²ÐÔÓÅÒ죬£¬£¬£¬£¬£¬£¬ÎÞDLT£¬£¬£¬£¬£¬£¬£¬Î´ÊӲ쵽CRS¡¢ICANSµÈ¸±×÷Óᣡ£¡£¡£¡£¡£Á½Àý»¼Õß»ØÊäºó¾ù»ñµÃ²¿·Ö»º½â£¨PR£©£¬£¬£¬£¬£¬£¬£¬1ÀýÒ»Á¬»º½âÖÁM3Ö×Áö°Ð²¡ÔîÏûÊÅ£¬£¬£¬£¬£¬£¬£¬µÖ´ïÍêÈ«»º½â£¨CR£©£¬£¬£¬£¬£¬£¬£¬ÁÙ´²ÁÆЧÏÔÖø¡£¡£¡£¡£¡£¡£

BZE2204£ºÊ׿î·Ç²¡¶¾¹¤Òյij¬¿ìËÙÎÞ×÷ÓýÈý°ÐµãѪҺÖ×ÁöCAR-T²úÆ·

ÕªÒªÎÊÌ⣺JL-Lightning CAR-T£¬£¬£¬£¬£¬£¬£¬a Next Generation Non-viral CAR-T without In-Vitro Culturing Procedure, Shows High Clinical Efficacy, Good Safety with Low Dosage

·Ö»á³¡Ö÷Ì⣺Adoptive Cell Therapy 1

±àºÅ£º3173

ʱ¼ä£ºÃÀ¹úÖв¿Ê±¼ä4ÔÂ28ÈÕ£¨ÖÜÒ»£©2:00 PM-5:00 PM

ËùÔÚ£ºµÚ27Çø£¬£¬£¬£¬£¬£¬£¬Õ¹°å#1

BZE2204´îÔؼ¯ÍÅJL-ÉÁCAR-T™ÊÖÒÕƽ̨£¬£¬£¬£¬£¬£¬£¬½öÐè6hÍê³É´Óµ¥²ÉѪµ½ÖƼÁµÄÈ«Àú³Ì£¬£¬£¬£¬£¬£¬£¬×îºéÁ÷ƽ°ü¹ÜTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄ·Ö½â±íÐͺÍÀ©ÔöÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬ÔÚÁÙ´²Ç°¶¯ÎïÊý¾ÝºÍIITÁÙ´²ÊµÑéÉ϶¼Õ¹ÏÖ³öÁËÓÅÒìµÄ¿¹Ö×ÁöЧ¹û£¬£¬£¬£¬£¬£¬£¬Êdz¬¿ìËÙCAR-TÖƱ¸ÊÖÒÕÁ¢ÒìÓë¶à°ÐµãCARÉè¼ÆÁ¢ÒìµÄϸÄåÍŽᡣ¡£¡£¡£¡£¡£BZE2204ÌåÄÚÀ©ÔöÄÜÁ¦Ç¿£¬£¬£¬£¬£¬£¬£¬ÒÔͨÀýÊÐÊÛCAR-T¼ÁÁ¿µÄ1/40£¬£¬£¬£¬£¬£¬£¬µÖ´ïͨÀý¼ÁÁ¿²úÆ·30-200±¶µÄ Cmax (CAR-T/ul)¡¢17-150±¶µÄAUC(CAR-T/ul*d)¡£¡£¡£¡£¡£¡£ÏÖÔÚ¿ªÕ¹µÄIITÁÙ´²ÊµÑéÖУ¬£¬£¬£¬£¬£¬£¬ÔÚr/r NHLÄ©Ïß»¼ÕßÖеִïÁÙ´²¿Í¹Û»º½âÂÊORR=100%£¬£¬£¬£¬£¬£¬£¬ÍêÈ«»º½âÂÊ£¨CR£©½ü70%£¬£¬£¬£¬£¬£¬£¬ÇÒ¶¾¸±×÷Óü«Ð¡£¬£¬£¬£¬£¬£¬£¬ÎÞÈý¼¶»òÒÔÉÏCRS£¬£¬£¬£¬£¬£¬£¬ÎÞDLT¡£¡£¡£¡£¡£¡£»£»£»£»£»¼Õß»ØÊäºó»Ö¸´ºÃ£¬£¬£¬£¬£¬£¬£¬Ò»Á¬»º½â±ÈÀý¸ß¡£¡£¡£¡£¡£¡£

CT111£ºÒ»¿îȫеÄÈý°ÐÏòÌØÒìÐÔÄÉÃ׿¹Ìå

ÕªÒªÎÊÌ⣺CT111, a novel trispecific PD-1*CTLA-4*VEGF single-domain antibody, synergistically targets exhausted T cells and promotes cooperative antitumor effects

·Ö»á³¡Ö÷Ì⣺Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators

±àºÅ£º6068

ʱ¼ä£ºÃÀ¹úÖв¿Ê±¼ä4ÔÂ29ÈÕ£¨Öܶþ£©2:00 PM-5:00 PM

ËùÔÚ£ºµÚ37Çø£¬£¬£¬£¬£¬£¬£¬Õ¹°å#9

CT111ÊÇ»ùÓÚµÚËÄ´úÄÉÃ׿¹ÌåVHHMAb^®ÊÖÒÕƽ̨¿ª·¢µÄÒ»¿îÈý°Ðµã(PD1*CTLA4*VFGF)ÌØÒìÐÔÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÕûºÏË«ÖØÃâÒß¼ì²éµãºÍVEGF×è¶Ï×÷Ó㬣¬£¬£¬£¬£¬£¬´Ó¶øЭͬսʤʵÌåÁöÄÚµÄÃâÒßÒÖÖÆÇéÐΣ¬£¬£¬£¬£¬£¬£¬ÔÚPBMCÈËÔ´»¯Ö×ÁöÄ£×ÓÖÐÕ¹ÏÖ³öÏÔÖøµÄ¿¹Ö×Áö»îÐÔ¡£¡£¡£¡£¡£¡£CT111ÔÚELISA¡¢ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾FACS¡¢Octet BLIµÈ¶àÖÖ¼ì²âÖоùÕ¹ÏÖ³öÓÅÒìµÄµ¥°Ð¼°¶à°ÐÍŽáÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°¾«²ÊµÄÅäÌå×è¶ÏЧ¹û; Í¬Ê±ÔÚÃâÒß¹¦Ð§¼¤»îЧ¹ûÉÏÏÔÖøÔöÇ¿£¬£¬£¬£¬£¬£¬£¬²»µ«ÔÚCMV recallºÍSEB´Ì¼¤ÊÔÑéÖÐÏÔÖøÌáÉýÁËIFN-γºÍIL-2µÄÉø͸£¬£¬£¬£¬£¬£¬£¬²¢ÇÒÓÐÓÃ×è¶ÏÁËVEGFÐźÅ£¬£¬£¬£¬£¬£¬£¬ÒÖÖÆHUVECÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÔöÖ³¡£¡£¡£¡£¡£¡£¸ÃÕ½ÂÔ²»µ«ÎªÌá¸ß¿¹Ö×ÁöÖÎÁÆЧ¹ûÌṩÁËȫмƻ®£¬£¬£¬£¬£¬£¬£¬Ò²ÎªÎ´À´¶à°ÐµãÃâÒßÖÎÁÆÒ©ÎïµÄÑз¢ºÍÁÙ´²×ª»¯¿ª·¢ÁËÕ¸ÐÂõ辶£¬£¬£¬£¬£¬£¬£¬Õ¹ÏÖ³öÁÉÀ«µÄÁÙ´²Ó¦ÓÃÔ¶¾°¡£¡£¡£¡£¡£¡£

CT224£ºÒ»ÏµÁп¹CD3ÒÔ¼°Ö×ÁöÌØÒìÐ԰еãµÄÄÉÃ׿¹Ìå

ÕªÒªÎÊÌ⣺A novel CD3 VHH—based multi-specific T cell engager platform and multiple leads for gastric cancer and auto-immune disease

·Ö»á³¡Ö÷Ì⣺Experimental and Molecular Therapeutics

±àºÅ£º5465

ʱ¼ä£ºÃÀ¹úÖв¿Ê±¼ä4ÔÂ29ÈÕ£¨Öܶþ£©2:00 PM-5:00 PM

ËùÔÚ£ºµÚ15Çø, Õ¹°å#23

ʹÓÃVHHMAb^®Æ½Ì¨£¬£¬£¬£¬£¬£¬£¬¿ª·¢ÁËһϵÁп¹CD3ÒÔ¼°Ö×ÁöÌØÒìÐ԰еãµÄÄÉÃ׿¹Ì壨VHH£©£¬£¬£¬£¬£¬£¬£¬ÕâЩ¿¹ÌåÔÚÍŽ᷽·¨¡¢Ç׺ÍÁ¦¡¢¼¤»îTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÄÜÁ¦ÒÔ¼°Õë¶Ô¶àÖÖÖ×Áö¿¹Ô­TAA£¨ÀýÈçCDH17, BCMA, CD19£©µÄ²î±ð½á¹¹ÓòÉϾùÌåÏÖ³öÏÔÖø¶àÑùÐÔ¡£¡£¡£¡£¡£¡£

CD3£ºÀֳɻñµÃÁ˲î±ðˮƽÈËÔ´»¯£¬£¬£¬£¬£¬£¬£¬¾ß±¸µÍÃâÒßÔ­ÐԵĿ¹CD3 VHH¿â£¬£¬£¬£¬£¬£¬£¬º­¸ÇÁËCD3¸´ºÏÎïµÄ²î±ð±íλ¡¢Ç׺ÍÁ¦¼°TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»îÌØÕ÷£¬£¬£¬£¬£¬£¬£¬ÎªTCE¹¹½¨ÌṩÁ˸»ºñºòÑ¡×ÊÔ´¡£¡£¡£¡£¡£¡£

CT224 (CDH17*CD3 TCE)£ºÕë¶Ô½áÖ±³¦°©ÖÐÌØÒìÐԸ߱í´ïµÄCDH17ÓÅÖʰе㣬£¬£¬£¬£¬£¬£¬»ñµÃÁË°ÐÏò7¸ö²î±ð½á¹¹ÓòÒÔ¼°²î±ðÖÖÊô£¨ÈË/ºï/Ê󣩵ÄVHH·Ö×Ó£¬£¬£¬£¬£¬£¬£¬¹¹½¨µÄCT224TCE ºòÑ¡·Ö×ÓÔÚÌåÍâɱÉËÊÔÑéÖÐÌåÏÖ¾«²Ê£¬£¬£¬£¬£¬£¬£¬ÆäɱÉË»îÐÔºÍÂÑ°×ÖÊÁ¿¾ùÓÅÓÚ¾ºÆ·£¬£¬£¬£¬£¬£¬£¬¾ß±¸ÓÅÒìµÄ¿ª·¢ÊôÐÔ¡£¡£¡£¡£¡£¡£

CT222 (CD19*BCMA*CD3 TCE)£ºÎªÕ½Ê¤¼òµ¥°ÐµãÖÎÁÆÖп¹Ô­ÌÓÒÝÎÊÌ⣬£¬£¬£¬£¬£¬£¬Àֳɿª·¢³ö¶à°ÐµãTCE£¨CT222£©, ¿ÉÒÔÔ½·¢ÖÜÈ«ºÍÉî¶ÈµÄɨ³ý°ÐµãÑôÐÔµÄÒì³£B»ò½¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬£¬ÓÃÓÚBÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ö×ÁöºÍ×ÔÃâ¼²²¡µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£

±¾Ñо¿ÕûºÏ¶àÖÖÃâÒßÕ½ÂÔ£¬£¬£¬£¬£¬£¬£¬Á¢ÒìÐԵع¹½¨ÁËÒÔVHHΪ½¹µãµÄTCEÐÂƽ̨£¬£¬£¬£¬£¬£¬£¬²»µ«ÎªÊµÌåÁöÖÎÁÆÌṩÁ˾«×¼ÇÒ¸ßЧµÄ¿¹Ìå½â¾ö¼Æ»®£¬£¬£¬£¬£¬£¬£¬Ò²Îª×ÔÉíÃâÒß¼²²¡´øÀ´Á˶à°ÐµãÍŽáÖÎÁƵÄÍ»ÆÆ£¬£¬£¬£¬£¬£¬£¬¾ßÓÐÍ»ÆÆÐÔµÄÁÙ´²Ó¦ÓÃDZÁ¦¡£¡£¡£¡£¡£¡£

CARP£º»ùÓÚÈ˹¤ÖÇÄܵÄVHH¸ßͨÁ¿É¸Ñ¡Æ½Ì¨

ÕªÒªÎÊÌ⣺CARP: A High-Throughput Platform for Rapid VHH Discovery of Potent CAR-T Therapy

·Ö»á³¡Ö÷Ì⣺High-Throughput Screening Assays and Libraries

±àºÅ£º3158

ʱ¼ä£ºÃÀ¹úÖв¿Ê±¼ä4ÔÂ28ÈÕ£¨ÖÜÒ»£©2:00 PM-5:00 PM

ËùÔÚ£ºµÚ25Çø, Õ¹°å#11

ͨ¹ýCARP£¨CAR-T AI-powered Rapid high-throughput screening Platform£©¶Ô¹¹½¨°ÐÏòCDH17 CARµÄVHH¾ÙÐиßͨÁ¿É¸Ñ¡£¬£¬£¬£¬£¬£¬£¬È¡µÃÁËÒÔÏÂÖ÷Òª·¢Ã÷£º

¿ìËÙ¸ßЧɸѡ£¡£¡£¡£¡£¡£ºÔÚ>400 VHH¹¹½¨µÄÎÄ¿âÖÐͨ¹ýAIƽ̨¾ÙÐбíλÆ×ϵÆÊÎö¡¢ÈËÔ´»¯¼°ÃâÒßÔ­ÐÔÆÀ¹À£¬£¬£¬£¬£¬£¬£¬ÍŽáÄ£ÄâÖ×Áö-CAR-Tºã¾Ã»¥×÷µÄ¹¦Ð§¹²×÷ÓýʵÑ飬£¬£¬£¬£¬£¬£¬Ò»´ÎÐÔ¾«×¼ÅжϾßÓи߶ÈÒ»Á¬ÔöֳɱÉËÄÜÁ¦µÄVHHºòÑ¡Î£¬£¬£¬£¬£¬£¬´Ó¶øÏÔÖøËõ¶ÌÑз¢ÖÜÆÚ¡£¡£¡£¡£¡£¡£

¸ßÖÊÁ¿ÖÀÖÐÂÊ£ºÊ¹Óúã¾ÃÀ©ÔöЧÂÊÆÀ¹À±ê×¼£¬£¬£¬£¬£¬£¬£¬¶Ôɸѡ»ñµÃµÄ20¸öÑôÐÔ¿Ë¡¾ÙÐй¦Ð§ÑéÖ¤£¬£¬£¬£¬£¬£¬£¬Ð§¹ûÑéÖ¤ÁËCARPƽ̨ÔÚɸѡĿµÄVHHÓÃÓÚ¹¹½¨ÀíÏëCARµÄ׼ȷÐÔ¡£¡£¡£¡£¡£¡£

ÓÅÖʱíλʶ±ð£º±¾Æ½Ì¨ÀÖ³Éɸѡµ½¶à¸öÕë¶ÔCDH17ÏàͬҪº¦½á¹¹ÓòµÄVHH£¬£¬£¬£¬£¬£¬£¬ÕâЩ·Ö×ÓÔÚÄ¿µÄÒÀÀµÐÍCAR-TÔöÖ³ÉÏÓÅÓÚ¶Ô±êºÍ¹Å°åɸѡ»ñµÃµÄVHH£¬£¬£¬£¬£¬£¬£¬ÎªºóÐøÁÙ´²¿ª·¢µÓÚ¨Á˼áʵ»ù´¡¡£¡£¡£¡£¡£¡£

×èÖ¹Öظ´ÃâÒߣºÒ»µ©Í¨¹ýCARPÍê³É³õɸÓëÃâÒßÔ­ÐÔÆÀ¹À£¬£¬£¬£¬£¬£¬£¬ÎÞÐèÔÙ´ÎÃâÒß»òÌØÊâÑéÖ¤£¬£¬£¬£¬£¬£¬£¬ÄÜÓÐÓýµµÍ×ÊԴͶÈëÓëÑз¢±¾Ç®¡£¡£¡£¡£¡£¡£

Õë¶Ô¹Å°åCAR-T¿¹Ìå·¢Ã÷µÄÆ¿¾±£¬£¬£¬£¬£¬£¬£¬CARPÔÚ¸ßͨÁ¿¡¢¸ßËÙÂÊ¡¢¸ßЧÂʵÄɸѡ¹¦Ð§ÐÔVHH·½ÃæÕ¹ÏÖÁËÏÔÖøÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬ÎªCAR-TÁÆ·¨µÄÉú³¤ÌṩÁ˾«×¼¡¢¿ÉÀ©Õ¹µÄÐÂ˼Ð÷£¬£¬£¬£¬£¬£¬£¬ÓÐÍû½øÒ»²½Íƶ¯CAR-TÁìÓòµÄ²úÆ·Á¢ÒìºÍÁÙ´²×ª»¯¡£¡£¡£¡£¡£¡£